title: Light-induced racemization: artifacts in the analysis of the diastereoisomeric pairs of thioridazine 5-sulfoxide in the plasma and urine of patients treated with thioridazine.
abstract: The ring sulfoxidation of thioridazine (THD), a widely used neuroleptic agent, yields two diastereoisomeric pairs, fast- and slow-eluting (FE and SE) thioridazine 5-sulfoxide (THD 5-SO). Until now, studies in which concentrations of these metabolites were measured in THD-treated patients have revealed no significant differences in their concentrations. Preliminary experiments in our laboratory had shown that sunlight and, to a lesser extent, dim daylight led to racemization and probably also to photolysis of the diastereoisomeric pairs as measured by high-performance liquid chromatography. Similar results were also obtained with direct UV light (UV lamp). In appropriate light-protected conditions, THD, northioridazine, mesoridazine, sulforidazine, and FE and SE THD 5-SO were measured in 11 patients treated with various doses of THD for at least 1 week. Significantly higher concentrations of the FE stereoisomeric pair were found. The concentration ratios THD 5-SO (FE)/THD 5-SO (SE) ranged from 0.89 to 1.75 in plasma and from 1.15 to 2.05 in urine. Because it is known that the ring sulfoxide contributes to the cardiotoxicity of the drug even more potently than the parent compound does, these results justify further studies to determine whether there is stereoselectivity in the cardiotoxicity of THD 5-SO.
authors.affiliation: Département Universitaire de Psychiatrie Adulte, Hôpital de Cery, Prilly-Lausanne, Switzerland.
authors.forename: C B
authors.initials: CB
authors.lastname: Eap
authors.forename: A
authors.initials: A
authors.lastname: Souche
authors.forename: L
authors.initials: L
authors.lastname: Koeb
authors.forename: P
authors.initials: P
authors.lastname: Baumann
mesh_terms: D000328:Adult; D000928:Antidepressive Agents / Q000097:blood / Q000652:urine; D002851:Chromatography, High Pressure Liquid; D005260:Female; D006801:Humans; D008027:Light; D008297:Male; D001523:Mental Disorders / Q000188:drug therapy; D008653:Mesoridazine / Q000097:blood / Q000652:urine; D008875:Middle Aged; D010640:Phenothiazines / Q000097:blood / Q000652:urine; D013237:Stereoisomerism; D013881:Thioridazine / Q000031:analogs & derivatives* / Q000032:analysis / Q000097:blood / Q000378:metabolism / Q000627:therapeutic use* / Q000652:urine
chemical_list: D000928:Antidepressive Agents; D010640:Phenothiazines; C072659:northioridazine; D008653:Mesoridazine; C041140:thioridazine-5-sulfoxide; C040634:sulforidazine; D013881:Thioridazine